Logo image of FEMY

FEMASYS INC (FEMY) Stock Fundamental Analysis

NASDAQ:FEMY - Nasdaq - US31447E1055 - Common Stock - Currency: USD

0.8769  +0 (+0.17%)

After market: 0.8749 0 (-0.23%)

Fundamental Rating

2

FEMY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. FEMY has a bad profitability rating. Also its financial health evaluation is rather negative. FEMY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FEMY has reported negative net income.
In the past year FEMY has reported a negative cash flow from operations.
In the past 5 years FEMY always reported negative net income.
In the past 5 years FEMY always reported negative operating cash flow.
FEMY Yearly Net Income VS EBIT VS OCF VS FCFFEMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

FEMY's Return On Assets of -159.02% is on the low side compared to the rest of the industry. FEMY is outperformed by 91.44% of its industry peers.
FEMY's Return On Equity of -1057.44% is on the low side compared to the rest of the industry. FEMY is outperformed by 90.37% of its industry peers.
Industry RankSector Rank
ROA -159.02%
ROE -1057.44%
ROIC N/A
ROA(3y)-89.97%
ROA(5y)-77.42%
ROE(3y)-322.97%
ROE(5y)-238.66%
ROIC(3y)N/A
ROIC(5y)N/A
FEMY Yearly ROA, ROE, ROICFEMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 66.24%, FEMY is in the better half of the industry, outperforming 69.52% of the companies in the same industry.
In the last couple of years the Gross Margin of FEMY has declined.
FEMY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y-2.71%
FEMY Yearly Profit, Operating, Gross MarginsFEMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

0

2. Health

2.1 Basic Checks

FEMY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FEMY has more shares outstanding
Compared to 5 years ago, FEMY has more shares outstanding
The debt/assets ratio for FEMY is higher compared to a year ago.
FEMY Yearly Shares OutstandingFEMY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
FEMY Yearly Total Debt VS Total AssetsFEMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

FEMY has an Altman-Z score of -17.17. This is a bad value and indicates that FEMY is not financially healthy and even has some risk of bankruptcy.
FEMY has a worse Altman-Z score (-17.17) than 88.24% of its industry peers.
FEMY has a Debt/Equity ratio of 2.89. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of FEMY (2.89) is worse than 88.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.89
Debt/FCF N/A
Altman-Z -17.17
ROIC/WACCN/A
WACC7.67%
FEMY Yearly LT Debt VS Equity VS FCFFEMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

FEMY has a Current Ratio of 0.93. This is a bad value and indicates that FEMY is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.93, FEMY is not doing good in the industry: 91.44% of the companies in the same industry are doing better.
FEMY has a Quick Ratio of 0.93. This is a bad value and indicates that FEMY is not financially healthy enough and could expect problems in meeting its short term obligations.
FEMY has a Quick ratio of 0.54. This is amonst the worse of the industry: FEMY underperforms 92.51% of its industry peers.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.54
FEMY Yearly Current Assets VS Current LiabilitesFEMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

6

3. Growth

3.1 Past

FEMY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.33%.
The Revenue has grown by 62.05% in the past year. This is a very strong growth!
Measured over the past years, FEMY shows a quite strong growth in Revenue. The Revenue has been growing by 11.86% on average per year.
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.29%
Revenue 1Y (TTM)62.05%
Revenue growth 3Y11.35%
Revenue growth 5Y11.86%
Sales Q2Q%25.86%

3.2 Future

FEMY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.13% yearly.
The Revenue is expected to grow by 117.00% on average over the next years. This is a very strong growth
EPS Next Y23.8%
EPS Next 2Y26.65%
EPS Next 3Y18.21%
EPS Next 5Y18.13%
Revenue Next Year128.46%
Revenue Next 2Y144.2%
Revenue Next 3Y145.11%
Revenue Next 5Y117.01%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FEMY Yearly Revenue VS EstimatesFEMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
FEMY Yearly EPS VS EstimatesFEMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FEMY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FEMY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FEMY Price Earnings VS Forward Price EarningsFEMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FEMY Per share dataFEMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

FEMY's earnings are expected to grow with 18.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.65%
EPS Next 3Y18.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FEMY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FEMASYS INC

NASDAQ:FEMY (7/23/2025, 8:22:41 PM)

After market: 0.8749 0 (-0.23%)

0.8769

+0 (+0.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06
Inst Owners12.06%
Inst Owner Change-0.68%
Ins Owners10.57%
Ins Owner Change5.27%
Market Cap28.53M
Analysts82
Price Target7.4 (743.88%)
Short Float %0.73%
Short Ratio0.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.28%
Min EPS beat(2)-21.89%
Max EPS beat(2)-18.68%
EPS beat(4)0
Avg EPS beat(4)-19.25%
Min EPS beat(4)-21.89%
Max EPS beat(4)-17.65%
EPS beat(8)2
Avg EPS beat(8)-9.65%
EPS beat(12)5
Avg EPS beat(12)-4.41%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-68.03%
Min Revenue beat(2)-70.71%
Max Revenue beat(2)-65.36%
Revenue beat(4)0
Avg Revenue beat(4)-56.25%
Min Revenue beat(4)-72.34%
Max Revenue beat(4)-16.58%
Revenue beat(8)1
Avg Revenue beat(8)-37.83%
Revenue beat(12)1
Avg Revenue beat(12)-30.36%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)0%
EPS NY rev (3m)-29.59%
Revenue NQ rev (1m)28.06%
Revenue NQ rev (3m)-43.6%
Revenue NY rev (1m)15.67%
Revenue NY rev (3m)-29.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.79
P/FCF N/A
P/OCF N/A
P/B 14.29
P/tB 14.72
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.05
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -159.02%
ROE -1057.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.24%
FCFM N/A
ROA(3y)-89.97%
ROA(5y)-77.42%
ROE(3y)-322.97%
ROE(5y)-238.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y-2.71%
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 2.89
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.92%
Cap/Sales 50.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.54
Altman-Z -17.17
F-Score4
WACC7.67%
ROIC/WACCN/A
Cap/Depr(3y)62.1%
Cap/Depr(5y)48.65%
Cap/Sales(3y)33.12%
Cap/Sales(5y)25.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.29%
EPS Next Y23.8%
EPS Next 2Y26.65%
EPS Next 3Y18.21%
EPS Next 5Y18.13%
Revenue 1Y (TTM)62.05%
Revenue growth 3Y11.35%
Revenue growth 5Y11.86%
Sales Q2Q%25.86%
Revenue Next Year128.46%
Revenue Next 2Y144.2%
Revenue Next 3Y145.11%
Revenue Next 5Y117.01%
EBIT growth 1Y-32.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-87.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-84.77%
OCF growth 3YN/A
OCF growth 5YN/A